|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Tumor Biology |
Department of Neurosurgery (A.W., W.C.L.) and Graduate Program in Neuroscience (W.C.L.), University of Minnesota Medical School, Minneapolis, MN 55455, USA, and Department of Neurosurgery, First Clinical College of China Medical University, Shenyang, China (A.W.)
2 Address correspondence to Walter C. Low, Department of Neurosurgery, University of Minnesota Medical School, 2001 Sixth Street, SE, Minneapolis, MN 55455, USA (lowwalt{at}umn.edu).
Abstract
The interleukin 13 alpha 2 receptor (IL-13Ra2) has been shown to be expressed in most malignant glioblastoma cells. Recent studies suggest that IL-13Ra2 serves as a dominant negative inhibitor or a decoy receptor for IL-13. To investigate the transcriptional regulation of this receptor, we cloned and characterized the promoter for the human IL-13Ra2 gene. Our results demonstrate that this promoter contains three TATA boxes and one CCAAT site. Several putative transcriptional factor binding sites for nuclear factor of activated T cells 1, AP1 (c-JUN and c-FOS), AP2, GABP, OCT1, GATA3, PRE, and C-ETS1 were predicted in the promoter region. Using the secreted alkaline phosphate reporter gene assay, we investigated the functional activity of the human IL-13Ra2 promoter by transient transfection in glioma cell lines U118, U87, and T98, which differ in their expression of the human IL-13Ra2 protein. The different secreted alkaline phosphate activities among these 3 cell lines suggest that the expression of human IL-13Ra2 is regulated at the transcriptional level. Methylation analysis showed that expression of IL-13Ra2 may not be the result of methylation of the CpG dinucleotides in the promoter region of the gene. Deletion analysis identified a 64 base pair (bp) region that is necessary for human IL-13Ra2 promoter activity. This 64-bp sequence contains cis-elements for AP1, nuclear factor of activated T cells, and AP2. The possible role of AP1 in the regulation of human IL-13Ra2 promoter activity was suggested by in vitro mutagenesis and c-JUN N-terminal kinase inhibition analysis.
References
Assimakopoulou, M., and Varakis, J. (2001) AP-1 and heat shock protein 27 expression in human astrocytomas. J. Cancer Res. Clin. Oncol. 127,727 -732.[ISI][Medline]
Bennett, B.L., Sasaki, D.T., Murray, B.W., O'Leary, E.C., Sakata,
S.T., Xu, W., Leisten, J.C., Motiwala, A., Pierce, S., Satoh, Y., Bhagwat,
S.S., Manning, A.M., and Anderson, D.W. (2001) SP600125, an
anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl.
Acad. Sci. USA 98,13681
-13686.
Bernard, J., Treton, D., Vermot-Desroches, C., Boden, C., Horellou,
P., Angevin, E., Galanaud, P., Wijdenes, J., and Richard, Y.
(2001) Expression of interleukin 13 receptor in glioma and renal
cell carcinoma: IL13R
2 as a decoy receptor for IL13. Lab.
Invest. 81,1223
-1231.[CrossRef][ISI][Medline]
Caput, D., Laurent, P., Kaghad, M., Lelias, J.M., Lefort, S., Vita,
N., and Ferrara, P. (1996) Cloning and characterization of a
specific interleukin (IL)-13 binding protein structurally related to the IL-5
receptor alpha chain. J. Biol. Chem.
271,16921
-16926.
Chinenov, Y., and Kerppola, T.K. (2001) Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 20,2438 -2452.[CrossRef][ISI][Medline]
Chomarat, P., and Banchereau, J. (1998) Interleukin-4 and interleukin-13: Their similarities and discrepancies. Int. Rev. Immunol. 17,1 -52.[Medline]
Daines, M.O., and Hershey, G.K. (2002) A novel
mechanism by which interferon-
can regulate interleukin (IL)-13
responses. Evidence for intracellular stores of IL-13 receptor alpha-2 and
their rapid mobilization by interferon-gamma. J. Biol.
Chem. 277,10387
-10393.
David, M., Ford, D., Bertoglio, J., Maizel, A.L., and Pierre, J. (2001) Induction of the IL-13 receptor alpha2–chain by IL-4 and IL-13 in human keratinocytes: Involvement of STAT6, ERK and p38 MAPK pathways. Oncogene 20,6660 -6668.[CrossRef][ISI][Medline]
Debinski, W., Obiri, N.I., Powers, S.K., Pastan, I., and Puri, R.K. (1995) Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin. Cancer Res. 1,1253 -1258.[Abstract]
Debinski, W., Slagle, B., Gibo, D.M., Powers, S.K., and Gillespie, G.Y. (2000) Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J. Neurooncol. 48,103 -111.[CrossRef][Medline]
Donaldson, D.D., Whitters, M.J., Fitz, L.J., Neben, T.Y., Finnerty,
H., Henderson, S.L., O'Hara, R.M., Jr., Beier, D.R., Turner, K.J., Wood, C.R.,
and Collins, M. (1998) The murine IL-13 receptor alpha 2:
Molecular cloning, characterization, and comparison with murine IL-13 receptor
alpha 1. J. Immunol.
161,2317
-2324.
Hilton, D.J., Zhang, J.G., Metcalf, D., Alexander, W.S., Nicola,
N.A., and Willson, T.A. (1996) Cloning and characterization of a
binding subunit of the interleukin 13 receptor that is also a component of the
interleukin 4 receptor. Proc. Natl. Acad. Sci. USA
93,497
-501.
Huang, H.J., Sebastian, J., Strahl, B.D., Wu, J.C., and Miller,
W.L. (2001) Transcriptional regulation of the ovine
follicle-stimulating hormone-beta gene by activin and gonadotropin-releasing
hormone (GnRH): Involvement of two proximal activator protein-1 sites for GnRH
stimulation. Endocrinology
142,2267
-2274.
Husain, S.R., Joshi, B.H., and Puri, R.K. (2001) Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int. J. Cancer 92,168 -175.[CrossRef][ISI][Medline]
Joshi, B.H., Plautz, G.E., and Puri, R.K. (2000)
Interleukin-13 receptor alpha chain: A novel tumor-associated transmembrane
protein in primary explants of human malignant gliomas. Cancer
Res. 60,1168
-1172.
Kawakami, M., Leland, P., Kawakami, K., and Puri, R.K. (2000) Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. Oncol. Res. 12,459 -467.[ISI][Medline]
Kawakami, K., Taguchi, J., Murata, T., and Puri, R.K.
(2001a) The interleukin-13 receptor alpha2 chain: An essential
component for binding and internalization but not for
interleukin-13–induced signal transduction through the STAT6 pathway.
Blood 97,2673
-2679.
Kawakami, K., Takeshita, F., and Puri, R.K. (2001b)
Identification of distinct roles for a dileucine and a tyrosine
internalization motif in the interleukin (IL)-13 binding component IL-13
receptor alpha 2 chain. J. Biol. Chem.
276,25114
-25120.
Kawakami, K., Husain, S.R., Bright, R.K., and Puri, R.K. (2001c) Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Cancer Gene Ther. 8,861 -868.[CrossRef][ISI][Medline]
Kawakami, K., Kawakami, M., Joshi, B.H., and Puri, R.K.
(2001d) Interleukin-13 receptor-targeted cancer therapy in an
immunodeficient animal model of human head and neck cancer. Cancer
Res. 61,6194
-6200.
Kolch, W. (2000) Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J. 351,289 -305.
Li, R., Pei, H., and Watson, D.K. (2000) Regulation of Ets function by protein-protein interactions. Oncogene 19,6514 -6523.[CrossRef][ISI][Medline]
Liu, H., Jacobs, B.S., Liu, J., Prayson, R.A., Estes, M.L., Barnett, G.H., and Barna, B.P. (2000) Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: Non-neoplastic glia and low-grade astrocytoma differ from malignant glioma. Cancer Immunol. Immunother. 49,319 -324.[CrossRef][ISI][Medline]
Minty, A., Chalon, P., Derocq, J.M., Dumont, X., Guillemot, J.C., Kaghad, M., Labit, C., Leplatois, P., Liauzun, P., and Miloux, B. (1993) Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362,248 -250.[CrossRef][Medline]
Mintz, A., Gibo, D.M., Slagle-Webb, B., Christensen, N.D., and
Debinski, W. (2002) IL-13R2 is a glioma-restricted
receptor for interleukin-13. Neoplasia
4, 388-399.[CrossRef][ISI][Medline]
Nash, K.T., Thompson, J.P., and Debinski, W. (2001) Molecular targeting of malignant gliomas with novel multiply-mutated interleukin 13–based cytotoxins. Crit. Rev. Oncol. Hematol. 39,87 -98.[ISI][Medline]
NCBI. National Center for Biotechnology Information (2003) Database online. Bethesda, MD: National Institutes of Health. Cited March 25, 2003. Available at http://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?ORG=Hs&CID=25954
Quandt, K., Frech, K., Karas, H., Wingender, E., and Werner, T.
(1995) MatInd and MatInspector—new fast and versatile tools
for detection of consensus matches in nucleotide sequence data.
Nucleic Acids Res. 23,4878
-4884.
Rahaman, S.O., Sharma, P., Harbor, P.C., Aman, M.J., Vogelbaum,
M.A., and Haque, S.J. (2002) IL-13R2, a decoy receptor for
IL-13 acts as an inhibitor of IL-4–dependent signal transduction in
glioblastoma cells. Cancer Res.
62,1103
-1109.
Rao, A., Luo, C., and Hogan, P.G. (1997) Transcription factors of the NFAT family: Regulation and function. Annu. Rev. Immunol. 15,707 -747.[CrossRef][ISI][Medline]
Rolling, C., Treton, D., Pellegrini, S., Galanaud, P., and Richard, Y. (1996) IL-4 and IL-13 receptors share the gamma c chain and activate STAT6, STAT3 and STAT5 proteins in normal human B cells. FEBS Lett. 393,53 -56.[CrossRef][ISI][Medline]
Tang, L., Boroughs, K.L., Morales, T., Stedman, K., Sellins, K., Clarke, K., McDermott, M., Yang, S., and McCall, C. (2001) Recombinant canine IL-13 receptor alpha2–Fc fusion protein inhibits canine allergen-specific-IgE production in vitro by peripheral blood mononuclear cells from allergic dogs. Vet. Immunol. Immunopathol. 83,115 -122.[CrossRef][ISI][Medline]
Vogt, P.K. (2001) Jun, the oncoprotein. Oncogene 20,2365 -2377.[CrossRef][ISI][Medline]
Whitmarsh, A.J., and Davis, R.J. (1996) Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 74,589 -607.[CrossRef][ISI][Medline]
This article has been cited by other articles:
|
|
 |
|
  Y. Zhao, D. He, J. Zhao, L. Wang, A. R. Leff, E. Wm. Spannhake, S. Georas, and V. Natarajan Lysophosphatidic Acid Induces Interleukin-13 (IL-13) Receptor {alpha}2 Expression and Inhibits IL-13 Signaling in Primary Human Bronchial Epithelial Cells J. Biol. Chem., April 6, 2007; 282(14): 10172 - 10179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Alleman, R. L. Tabios, G. V. R. Chandramouli, O. N. Aprelikova, C. Torres-Cabala, A. Mendoza, C. Rodgers, N. A. Sopko, W. M. Linehan, and J. R. Vasselli The In vitro and In vivo Effects of Re-Expressing Methylated von Hippel-Lindau Tumor Suppressor Gene in Clear Cell Renal Carcinoma with 5-Aza-2'-deoxycytidine Clin. Cancer Res., October 15, 2004; 10(20): 7011 - 7021. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
